Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Teresa Casals"'
Autor:
Anant Shah, Teresa Delgado-Goni, Teresa Casals Galobart, Slawomir Wantuch, Yann Jamin, Martin O. Leach, Simon P. Robinson, Jeffrey Bamber, Mounia Beloueche-Babari
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Targeted therapies specific to the BRAF-MEK-ERK signaling pathway have shown great promise in the treatment of malignant melanoma in the last few years, with these drugs now commonly used in clinic. Melanoma cells treated using these agents
Externí odkaz:
https://doaj.org/article/70160c2970da4f94b357818550a07a16
Autor:
Martin O. Leach, Paul D. Smith, Thomas R. Eykyn, Yuen-Li Chung, Vaitha Arunan, Harold G. Parkes, Markella Koniordou, Teresa Casals Galobart, Slawomir Wantuch, Mounia Beloueche-Babari
This file contains Supplementary Materials, Methods and Figures relating to the manuscript as follows: Supplementary Materials: Antibodies for western blotting, Supplementary Methods: LDH activity assay, ATP measurements, confocal microscopy, histopa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966024c78405f162f38fbea61e8d5ace
https://doi.org/10.1158/0008-5472.22418604.v1
https://doi.org/10.1158/0008-5472.22418604.v1
Autor:
Martin O. Leach, Paul D. Smith, Thomas R. Eykyn, Yuen-Li Chung, Vaitha Arunan, Harold G. Parkes, Markella Koniordou, Teresa Casals Galobart, Slawomir Wantuch, Mounia Beloueche-Babari
Monocarboxylate transporters (MCT) modulate tumor cell metabolism and offer promising therapeutic targets for cancer treatment. Understanding the impact of MCT blockade on tumor cell metabolism may help develop combination strategies or identify phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fec8af20c602e53f0ed49d34b4f552d
https://doi.org/10.1158/0008-5472.c.6510174.v1
https://doi.org/10.1158/0008-5472.c.6510174.v1
Autor:
Mounia Beloueche-Babari, Teresa Casals Galobart, Martin O. Leach, Deimante Normantaite, Teresa Delgado-Goñi, Slawomir Wantuch, Steven R. Whittaker
Publikováno v:
British Journal of Cancer
Background BRAF inhibitors, such as vemurafenib, have shown efficacy in BRAF-mutant melanoma treatment but acquired-resistance invariably develops. Unveiling the potential vulnerabilities associated with vemurafenib resistance could provide rational
Autor:
Pasquale Rescigno, Lorenzo Buroni, Amanda Swain, Nicolás Herranz, Bora Gurel, Ruth Riisnaes, Alejandro Athie, Jan Rekowski, Natalia Castro, Wei Yuan, Christopher J. Lord, Adam Sharp, J. Carmichael, Sara Arce-Gallego, Joan Carles, Diletta Bianchini, Macarena Gonzalez, Ana Ferreira, Suzanne Carreira, Antje Neeb, Jesús Gil, Verena Wagner, George Seed, Alec Paschalis, Cristina Suarez, Daniel Nava Rodrigues, Veronica Gil, Maria de Los Dolores Fenor de la Maza, Caterina Aversa, Ines Figueiredo, Jian Ning, Irene Casanova-Salas, Johann S. de Bono, Teresa Casals, Rafael Morales-Barrera, Claudia Bertan, Joaquin Mateo, Sarai Cordoba, Khobe Chandran, Susana Miranda, Jon Welti, Violeta Serra
Publikováno v:
European Urology
Scientia
Scientia
Inhibició de l’ATR; Resposta de danys a l’ADN; Càncer de pròstata Inhibición de ATR; Respuesta al daño del ADN; Cancer de prostata ATR inhibition; DNA damage response; Prostate cancer Background Deleterious ATM alterations are found in metas
Autor:
Jose Luis, Marín Soria, Rosa Mª, López Galera, Ana, Argudo Ramírez, Jose Manuel, González de Aledo, Sonia, Pajares García, Aleix, Navarro Sastre, Jose Mª, Hernandez Pérez, Antonia, Ribes Rubio, Laura, Gort Mas, Judit, García Villoria, Silvia, Gartner Tizano, Sandra, Rovira Amigo, Oscar, Asensio de la Cruz, Miguel, García González, María, Cols Roig, Jordi, Costa Colomer, Celia, Bádenas Orquin, Diego, Yeste Fernández, Ariadna, Campos Martorell, María, Clemente León, Eduardo, Mogas Viñals, Roser, Ferrer Costa, Marina, Giralt Arnaiz, Jaume, Campistol Plana, Ángeles, García Cazorla, David, Beneitez Pastor, Ana, Ortuño Cabrero, Adoración, Blanco Álvarez, Barbara, Tazón Vega, Gael, Roué, Pablo, Velasco Puyo, Thais, Murciano Carrillo, Laura, Murillo Sanjuan, Cristina, Díaz de Heredia Rubio, Mª Del Mar, Mañú Pereira, Josep Lluis, Vives Corrons, José Antonio, Arranz Amo, Clara, Carnicer Cáceres, Mireia, Del Toro Riera, Aida, Ormazábal Herrero, Rafael, Artuch Iriberri, Camila, García-Volpe, Mariela Mercedes, de Los Santos, Cristina, Sierra March, Carlos José, Ruiz Hernández, Silvia Mª, Meavilla Olivas, Andrea, Martín Nalda, Jacques G, Rivière, Alba, Parra Martínez, Pere, Soler Palacín, Mónica, Martínez Gallo, Roger, Colobran, Teresa, Casals Senent, Mercè, Armelles Sebastia, Mª José, Vidal Benede, Mireia, Jané Checa, Rosa Mª, Fernández Bordón, Laia, Asso Ministral, Blanca, Prats Viedma, Carmen, Cabezas Peña
Publikováno v:
Revista espanola de salud publica. 94
The Catalonian Newborn Screening Program (CNSP) began in 1969, in Barcelona. It was promoted by Dr. Juan Sabater Tobella and supported by Barcelona Provincial Council and Juan March Foundation. That is how the Institute of Clinical Biochemistry was b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Thomas R. Eykyn, Yuen-Li Chung, Paul D. Smith, Markella Koniordou, Martin O. Leach, Teresa Casals Galobart, Harold G. Parkes, Vaitha Arunan, Mounia Beloueche-Babari, Slawomir Wantuch
Publikováno v:
Cancer Research. 77:5913-5924
Monocarboxylate transporters (MCT) modulate tumor cell metabolism and offer promising therapeutic targets for cancer treatment. Understanding the impact of MCT blockade on tumor cell metabolism may help develop combination strategies or identify phar
Autor:
Mounia Beloueche-Babari, Debbie Tandy, Teresa Delgado-Goñi, Martin O. Leach, James A. Harker, Slawomir Wantuch, Harold G. Parkes, Teresa Casals Galobart
Publikováno v:
British Journal of Cancer
Background Monocarboxylate transporter 1 (MCT1) is a regulator of cell metabolism and a therapeutic target for cancer treatment. Understanding the changes in tumour function accompanying MCT1 inhibition will better characterise the anti-tumour effect